MENU
+Compare
BIB
ETF ticker: NASDAQ
AS OF
Nov 19 closing price
Price
$76.39
Change
-$1.52 (-1.95%)
Net Assets
79.36M

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
BIB
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for BIB with price predictions
Nov 19, 2025

BIB's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BIB turned positive on November 11, 2025. Looking at past instances where BIB's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 225 cases where BIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BIB moved out of overbought territory on November 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIB broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology ETF is 7.22B. The market cap for tickers in the group ranges from 26.58M to 276.48B. AZN holds the highest valuation in this group at 276.48B. The lowest valued company is QTTB at 26.58M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 0%. For the same ETF, the average monthly price growth was 11%, and the average quarterly price growth was 78%. MRSN experienced the highest price growth at 211%, while APLT experienced the biggest fall at -69%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was -30% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 74
Price Growth Rating: 47
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com